Carter Gould Recent News
UBS Cuts Price Target On Celgene To $146 As GED Drops Out
'Poor Quality' Amgen Earnings Beat Doesn't Impress These Two Wall Street Analysts
19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug
The Near-Term Setup For Biogen Has Positive Risk/Reward Written All Over It
Analysts Confident In Acceleron Pharma's Drug Trial Outcomes
Acceleron's Luspatercept Is All About Duration, And This Analyst Is Excited About Its Prospects